1. In Vivo
  2. >>Global Vision

Sorin and ELA join Forces in Europe's Cardiovascular Market

Sorin's acquisition of French pacemaker leader ELA Medical creates one of Europe's largest and most diversified native cardiovascular device companies.

A couple of years ago, when Sulzer Medica Ltd. put its cardiac rhythm management business up for sale, Italian medical device leader Sorin Biomedica Cardio SPA , a division of Snia SPA , was one of the companies that bid for it. How seriously anyone took Sorin's bid is another question.

With this deal, Sorin, which is strong in cardiac surgery—particularly heart valves and, to a lesser degree, minimally-invasive cardiac surgery—and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By Ashley Yeo

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 
• By Sushmita Panda

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By David Wild

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.